Battery-Powered Skin Patch for PAD treatment

Scientists have confirmed the feasibility of using a new drug delivery system - the basis for a battery-powered skin patch - to administer medication that shows promise for treating peripheral artery disease (PAD) and healing stubborn skin ulcers and burns. The needle-free delivery of the medication, which cannot be given by mouth and can have side effects when injected, is reported in the ACS journal, Molecular Pharmaceutics.

Yogeshvar Kalia and colleagues explain that the medication consists of fibroblast growth factors (FGFs), proteins that have shown promise for treating skin conditions and PAD, which causes pain in the legs, buttocks, and feet due to blocked arteries in the legs. However, FGFs become inactive if given by mouth, and their injection can result in kidney and eye damage. The scientists had previously shown that a drug delivery technology called transdermal iontophoresis can deliver medicines made from small proteins. But would the technique, which involves encouraging medicine through the skin with a small electric current, work for larger proteins like FGFs?

Their laboratory tests with samples of human skin and pig skin showed that iontophoresis did work - in contrast, no FGF was delivered without electricity. Four times more medication remained in the skin than passed through which was also an advantage. Most importantly, the medicine remained biologically active in the skin. The results confirm the feasibility of using iontophoresis to deliver medicines consisting of larger proteins, including FGFs, the scientists note.

 

11.08.2011

More on the subject:

Related articles

Photo

News • OLE-induced microglia rewiring

Molecule “reprograms” the brain’s defenses against Alzheimer’s disease

A new experimental compound, called OLE, helps the brain enclose and contain beta-amyloid plaques – a hallmark of Alzheimer’s disease –, reducing their size and toxicity.

Photo

News • Intrahepatic cholestasis of pregnancy

ICP: Large-scale study sheds light on pregnancy-related liver disease

A new study uncovers new factors associated with ICP, a pregnancy-related liver disease. The findings open up new avenues for research into maternal health and pregnancy-related liver diseases.

Photo

News • Reviving exhausted immune cells

A new way to boost cancer immunotherapy

A Taiwanese research team found that BET inhibitors can restore exhausted T cells by reprogramming their metabolism – a potential new strategy for cancer immunotherapy.

Subscribe to Newsletter